Clinical Trials

This phase III trial compares the effect of adding carboplatin to the standard of care chemotherapy drug cabazitaxel versus cabazitaxel alone in treating prostate cancer that keeps growing even when the amount of testosterone in the body is reduced to very low levels (castrate-resistant) and that has spread from where it first started (primary site) to other places in the body (metastatic). Carboplatin is in a class of medications known as platinum-containing compounds. Carboplatin works by killing, stopping or slowing the growth of tumor cells. Chemotherapy drugs, such as cabazitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Prednisone is often given together with chemotherapy drugs. Prednisone is in a class of medications called corticosteroids. It is used to reduce inflammation and lower the body's immune response to help lessen the side effects of chemotherapy drugs and to help the chemotherapy work. Giving carboplatin with the standard of care chemotherapy drug cabazitaxel may be better at treating metastatic castrate-resistant prostate cancer.

MMC - Eau Claire Cancer Center

2200 Craig Road

Eau Claire, WI 54701

MMC - Marshfield

1000 N OAK AVE

MARSHFIELD, WI 54449

MMC - Minocqua

9601 TOWNLINE RD

MINOCQUA, WI 54548

MMC - Rice Lake

2501 Main

Stevens Point, WI 54481

MMC - River Region at Stevens Point

MMC - Weston

3501 CRANBERRY BLVD

WESTON, WI 54476

The purpose of this study is to obtain clinical specimens, supporting clinical information, and laboratory testing results from patients from the upper Midwestern United States with early (acute) LD or with evidence of Lyme arthritis (LA). The specimens and well-characterized patient data will become part of a national repository of serum samples maintained by the CDC National Center for Emerging and Zoonotic Infectious Diseases, Division of Vector-Borne Disease. The samples will be available for external requestors for use in developing and evaluating improved serologic tests for LD.

Eagle River Center

500 COMMERCE LOOP

EAGLE RIVER, WI 54521

Greenwood Center

102 W CANNERY STREET

GREENWOOD, WI 54437

Marshfield Medical Center - Rice Lake

1700 W STOUT ST

RICE LAKE, WI 54868

MC - Chippewa Falls Center

2655 CTY HWY I

CHIPPEWA FALLS, WI 54729

MC - Lake Hallie Center

12961 27TH AVE

CHIPPEWA FALLS, WI 54729

MC - Wausau Center

2727 PLAZA DRIVE

WAUSAU, WI 54401

MMC - Eau Claire

2116 Craig Rd

Eau Claire, WI 54701

MMC - Marshfield

1000 N OAK AVE

MARSHFIELD, WI 54449

MMC - Minocqua

9601 TOWNLINE RD

MINOCQUA, WI 54548

MMC - Neillsville

216 Sunset Place

Neillsville, Wisconsin 54456

MMC - Weston

3501 CRANBERRY BLVD

WESTON, WI 54476

Stratford Center

101 WISCONSIN AVE

STRATFORD, WI 54484

The Heartland Study is a prospective, observational study that will enroll up to 2,600 pregnant participants across the Heartland States in the U.S. The objective of the Heartland Study is to address major knowledge gaps concerning the health effects of herbicides on maternal and infant health. The study is being conducted to evaluate the associations between environmental exposures to herbicides during and after pregnancy and reproductive health outcomes. The study is measuring multiple biomarkers of herbicide exposure among pregnant Midwesterners and their partners to evaluate associations with pregnancy and childbirth outcomes, epigenetic biomarkers of exposure, and child development.

MMC - Marshfield

1000 N OAK AVE

MARSHFIELD, WI 54449

Patients are enrolled to screening (Reg Step 1) prior to or after ASCT but prior to Reg Step 2. Patients are followed until they will begin Maintenance and then registered to Reg Step 2 (first randomization). Patients are randomized between Lenalidomide for 2 years and Lenalidomide + Daratumumab/rHuPH20. After 2 years of Maintenance, MRD is assessed to guide further therapy. MRD-positive patients will continue with the assigned treatment. MRD-negative patients will be further randomized (Reg Step 3) to either continue or discontinue the assigned treatment. Patients are treated for up to 7 years from Step 2 reg and followed for up to 15 years.

Marshfield Medical Center - Rice Lake

1700 W STOUT ST

RICE LAKE, WI 54868

MMC - Eau Claire Cancer Center

2200 Craig Road

Eau Claire, WI 54701

MMC - Marshfield

1000 N OAK AVE

MARSHFIELD, WI 54449

MMC - Minocqua

9601 TOWNLINE RD

MINOCQUA, WI 54548

MMC - River Region at Stevens Point

MMC - Weston

3501 CRANBERRY BLVD

WESTON, WI 54476

This phase III trial compares the effect of geriatric evaluation and management with survivorship health education (GEMS) to usual care on patient-reported physical function in older survivors of cancer. Survivorship care for older adults of cancer usually consists of getting advice from their doctor. This advice may include how to do their daily activities, so they are less tired or how to manage multiple diseases, or long-term side effects from treatment. GEMS may help improve the physical ability to perform activities of daily living, mental well-being, and memory in older survivors of cancer after chemotherapy. This study may help doctors learn if including GEMS in their practices improves physical, mental and memory functions in their patients. The study may also help to understand how such care affects cancer patients and their caregivers' quality of life.

MMC - Marshfield

1000 N OAK AVE

MARSHFIELD, WI 54449

MMC - River Region at Stevens Point

MMC - Weston

3501 CRANBERRY BLVD

WESTON, WI 54476

This is a Prospective Observational Cohort Study, designed to better characterize patients with cancer cachexia (CC) by prospectively evaluating weight, muscle mass, fat mass, eating and appetite, physical function, symptoms, and associated medical and biopsychosocial factors. CC was defined by an international consensus panel as a “multifactorial syndrome characterized by an ongoing loss of skeletal muscle mass (with or without loss of fat mass) that cannot be fully reversed by conventional nutritional support and leads to progressive functional impairment1.” CC has been associated with reduced physical performance, impaired quality of life and poorer survival. Unfortunately, there currently are no Food and Drug Administration (FDA)-approved treatment for CC. Therefore, therapeutic development for CC is an urgent unmet need. The diagnostic criteria for CC as defined by the international consensus are as follows: a) greater than 5% weight loss in the previous 6 months or b) greater than 2% weight loss with either low Body Mass Index (BMI) or skeletal muscle depletion. A key criticism of the diagnostic criteria is that it is too broad and simplistic for a complex, multifactorial disease process and that it relies too heavily on weight, which is subject to change from a myriad of conditions. The aim of this study will be to develop new diagnostic criteria for CC subtypes so that pathophysiologic drivers of CC can be isolated in individuals and, ultimately, more tailored therapies can be developed.

MMC - Eau Claire Cancer Center

2200 Craig Road

Eau Claire, WI 54701

MMC - Marshfield

1000 N OAK AVE

MARSHFIELD, WI 54449

MMC - Minocqua

9601 TOWNLINE RD

MINOCQUA, WI 54548

MMC - Rice Lake

2501 Main

Stevens Point, WI 54481

MMC - River Region at Stevens Point

MMC - Weston

3501 CRANBERRY BLVD

WESTON, WI 54476

multi-site trial evaluating the efficacy and safety of the combination of 5-FU, oxaliplatin and nal-IRI (plus trastuzumab for HER2-positive tumors) as first-line therapy for patients with advanced EGA. Subjects will be enrolled into one of the two cohorts based on the HER2 status of the tumor. Subjects in Cohort 1 (HER2-negative) will be treated with 5-FU, oxaliplatin and nal-IRI. Subjects in Cohort 2 (HER2-positive) will be treated with trastuzumab in addition to 5-FU, oxaliplatin and nal-IRI.

Marshfield Medical Center - Rice Lake

1700 W STOUT ST

RICE LAKE, WI 54868

MMC - Eau Claire

2116 Craig Rd

Eau Claire, WI 54701

MMC - Marshfield

1000 N OAK AVE

MARSHFIELD, WI 54449

MMC - Minocqua

9601 TOWNLINE RD

MINOCQUA, WI 54548

MMC - River Region at Stevens Point

MMC - Weston

3501 CRANBERRY BLVD

WESTON, WI 54476

This study examines the impact of social and genetic factors on outcomes in adolescent and young adult (AYA) cancer survivors of Hodgkin or non-Hodgkin lymphoma. Compared to both older adult and childhood cancer patients, AYAs with cancer experience different diagnoses and specific biological, clinical, psychological and social factors that affect their risks for post-treatment morbidity and premature death. Collecting samples of blood samples and health and treatment information from cancer survivors of Hodgkin or non-Hodgkin lymphoma may help doctors identify conditions that increase the likelihood of AYAs getting sick and dying after treatment of cancer and better understand how to address the needs of adolescent and young adult cancer survivors.

MMC - Marshfield

1000 N OAK AVE

MARSHFIELD, WI 54449

Velos_Test_01042023

MMC - Marshfield

1000 N OAK AVE

MARSHFIELD, WI 54449

This multi-center, prospective, observational, feasibility study is designed to compare data collected by two FDA-cleared wearable devices: a) the Rhythm Express Wearable System, and b) Polysomnography (PSG).

MMC - Marshfield

1000 N OAK AVE

MARSHFIELD, WI 54449